Immutep (IMMP) Research & Development (2015 - 2017)
Immutep's (IMMP) quarterly Research & Development came in at $9.1 million in Q2 2017, down 3.54% YoY from $9.4 million in Q2 2016, and up 758.25% on a QoQ basis from -$1.4 million in Q1 2017.
Immutep (IMMP) Research & Development (2015 - 2017) Analysis & Trends
Immutep (IMMP) has 3 years of Research & Development data on file, last reported at $9.1 million in Q2 2017.
- Quarterly Research & Development fell 3.54% year-over-year to $9.1 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $16.0 million (changed N/A YoY) and the FY2020 annual result came in at $13.4 million, up 15.03% from the prior year.
- Research & Development rose to $9.1 million in Q2 2017, from -$1.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $9.4 million in Q2 2016 to a low of -$3.8 billion in Q2 2015.
- A 3-year average of -$757.4 million and a median of -$1.1 million in 2016 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2016 — Research & Development soared 100.25% — and 2017, when it dropped 27.11%.
- Tracing IMMP's Research & Development over 3 years: stood at -$3.8 billion in 2015, then soared by 100.25% to $9.4 million in 2016, then dropped by 3.54% to $9.1 million in 2017.
- The last three Research & Development figures came in at $9.1 million (Q2 2017), -$1.4 million (Q1 2017), and $9.4 million (Q2 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Immutep | 57.14 Mn | -7.95 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 9.05 Mn |
| Mar 31, 2017 | -1.38 Mn |
| Jun 30, 2016 | 9.38 Mn |
| Mar 31, 2016 | -1.08 Mn |
| Jun 30, 2015 | -3.80 Bn |